Benefits
Pregnancy nausea (NVP) — strongest evidence
meta-analysis (Nutr J 13:20) of 12 RCTs in 1,278 pregnant women showed ginger significantly improved nausea (MD 1.20, 95% CI 0.56-1.84) without significantly reducing vomiting episodes. ACOG and Society of Obstetricians and Gynaecologists of Canada include ginger as a first-line non-pharmacologic option. Subgroup analyses favor doses <1,500 mg/day.
Chemotherapy and postoperative nausea
Multiple RCTs and a 2024 umbrella review (Li et al., Int J Food Sci Nutr 75:122-133) confirm ginger reduces chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea, decreasing need for rescue antiemetics. Effect modest in magnitude but consistent. Reasonable adjunct to standard antiemetic regimens, not a replacement.
Osteoarthritis pain — modest effect
meta-analysis (Osteoarthritis Cartilage 23:13-21) of 5 placebo-controlled RCTs in 593 OA patients found ginger 'modestly efficacious' for pain and physical function. Effect size ~30% better than placebo, but ginger group was 2× as likely to discontinue. Not validated in head-to-head trials vs. NSAIDs at scale; one Wigler 2003 single trial only.
Exercise-induced muscle pain (DOMS)
RCT showed 2 g/day raw or heat-treated ginger reduced eccentric-exercise-induced arm muscle pain by 25-30%. Wilson 2018 (32 distance runners, 1.425 g/day × 5 days, downhill running protocol) showed reduced soreness and improved pain-pressure threshold. Effects most pronounced with 1-2 weeks pre-loading before unaccustomed exercise. Mechanism: COX-2 and prostaglandin E2 inhibition.
Blood sugar — mixed evidence
meta-analysis (10 RCTs, n=490) showed significant fasting glucose (-21.24 mg/dL) and HbA1c (-1.00%) reduction in T2D. However, a 2024 Clinical Nutrition ESPEN review of 5 RCTs (1.2-2 g/day, 4-12 weeks) found NO significant effect. Effect appears dose-dependent (>2 g/day in earlier positive trials). Mechanism: 6-gingerol activates PPAR-γ, inhibits alpha-glucosidase.
Anti-inflammatory and lipid effects
Multiple meta-analyses show ginger supplementation reduces CRP, IL-6, TNF-α, total cholesterol, LDL, and triglycerides — particularly in metabolic syndrome and inflammatory conditions. Effects are modest but consistent. Mechanism: dual COX-1/2 and 5-LOX inhibition (different from NSAIDs which only target COX), plus NF-κB pathway suppression and antioxidant activity.
Digestive health and motility
Ginger accelerates gastric emptying, reduces bloating, and improves GI motility — useful for functional dyspepsia, gastroparesis, and general digestive discomfort. Mechanism: 5-HT3 and 5-HT4 receptor modulation plus cholinergic enhancement. This same prokinetic activity is mechanistically linked to the anti-nausea effect (gastric stasis is a key trigger of nausea).
Dysmenorrhea (menstrual pain)
Multiple RCTs reviewed in Lete 2020 show 750-2,000 mg ginger over the first 3 days of menstruation reduces pain severity comparable to mefenamic acid and ibuprofen in young women. Mechanism: prostaglandin synthesis inhibition (same target as NSAID-class menstrual pain relief). A reasonable first-line option for those preferring botanical alternatives.
Mechanism of action
Dual COX and 5-LOX inhibition
Gingerols and shogaols inhibit cyclooxygenase-1 and -2 (COX-1/2) reducing prostaglandin synthesis, AND simultaneously inhibit 5-lipoxygenase (5-LOX) reducing leukotriene production. This dual pathway inhibition provides broader anti-inflammatory coverage than NSAIDs (COX-only) or Boswellia (5-LOX-only) individually.
5-HT3 receptor antagonism for anti-nausea effects
6-gingerol and 6-shogaol antagonize 5-HT3 (serotonin type 3) receptors in the GI tract and vomiting center — the same receptor blocked by ondansetron (Zofran), a leading antiemetic drug. This mechanism produces ginger's rapid anti-nausea effects without the adverse effects of pharmaceutical 5-HT3 antagonists.
PPAR-γ activation and insulin sensitization
6-gingerol activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving adipocyte differentiation, adiponectin secretion, and peripheral insulin sensitivity. This nuclear receptor mechanism explains ginger's metabolic benefits for blood sugar control and body composition beyond its anti-inflammatory activity.
Clinical trials
12 RCTs in 1,278 pregnant women. Ginger significantly improved nausea symptoms (MD 1.20, 95% CI 0.56-1.84, p=0.0002, I²=0%). Vomiting reduction trended toward significance (MD 0.72, 95% CI -0.03-1.46, p=0.06). Subgroup analyses favored daily doses <1,500 mg. Foundation for current obstetric guideline inclusion.
5 placebo-controlled RCTs, 593 OA patients (mainly knee/hip). Ginger was 'modestly efficacious' for pain (Hedges' SMD favoring ginger) and physical function. Adverse events were mild and reversible. Authors' caveat: ginger group was 2× as likely to discontinue treatment vs. placebo group, mostly due to GI tolerability. Evidence quality judged moderate (small samples, ITT issues).
10 RCTs, 490 T2D patients. Significant reduction in HbA1c (WMD -1.00%, 95% CI -1.56 to -0.44, p<0.001) and fasting glucose (WMD -21.24 mg/dL, p<0.001). Note: a 2024 Clinical Nutrition ESPEN review of 5 lower-dose RCTs (1.2-2 g/day, 4-12 weeks) found NO significant effect — suggesting effect may be dose-dependent.
32 distance runners, 1.425 g/day ginger × 5 days before downhill running protocol. Reduced muscle soreness and improved pain-pressure threshold post-exercise vs. placebo. Builds on Black 2010 (2 g/day reduced eccentric-exercise muscle pain by 25-30%). Effects strongest with 1-2 week pre-exercise loading.
10 high-quality RCTs evaluating ginger supplementation for hyperemesis gravidarum (severe pregnancy nausea). Ginger comparable to vitamin B6 and metoclopramide for symptom relief in mild-to-moderate HG, with favorable safety profile. Severe HG generally still requires conventional antiemetic therapy.